Skip to main content

Table 1 Base line

From: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

Volunteers characteristics
Variable Total (n = 46)
Age (years)
 Mean 46.4 (±9.7)
 Median (Q1–Q3) 47.0 [42.0–51.5]
Sexe n (%) woman 13 (27 %)
HIV infection diagnosis (years)
 Mean 12.4 (±7.9)
 Median (Q1–Q3) 12.0 [4.8–20.3]
Years since HIV RNA <40 copies/mL
 Mean 6.0 (±4.3)
 Median (Q1–Q3) 4.6 [2.1–9.7]
ART
 Nucleoside base 1 (2.1 %)
 Non nucleosidic 28 (58.3 %)
 Protease 15 (31.3 %)
 Integrase 4 (8.3 %)
HIV DNA (copies/106 PBMC)
 Mean 86.7 (±117.2)
 Median (Q1–Q3) 49.5 [1.0–111.0]
Log HIV DNA
 Mean 1.7 (±0.5)
 Median (Q1–Q3) 1.7 [0.0–2.1]
CD4 (cells per µL)
 Mean 692.4 (±259.6)
 Median 666.0 [515.0–791.5]
CD8 (cells per µL)
 Mean 688.3 (±309.8)
 Median (Q1–Q3) 654.0 [475.0–753.0]
CD4/CD8
 Mean 1.1 (±0.4)
 Median (Q1–Q3) 1.1 [0.8–1.4]
Nadir (CD4 <350 cells per µL) (years)
 Mean 5.8 (±4.9)
 Median (Q1–Q3) 4.4 [2.0–8.3]
Nadir CD4 (cells per µL)
 Mean 336.3 (±114.0)
 Median (Q1–Q3) 312.0 [265.0–390.0]